- Recruiting
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
Updated: Jun 27, 2022
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
This study will test the safety of TTI-621 or TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose of TTI-621 and TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each study drug, they will further test the combinations (TTI-621 + daratumumab hyaluronidase-fihj and TTI-622 + daratumumab hyaluronidase-fihj) in new participants to find out if the combinations are effective in treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may be an effective treatment approach.
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
Trillium Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT05139225
A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-621 Or TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma
First Posted : December 1, 2021
Click here to see details on ClinicalTrials.gov
Drug: TTI-621
Drug: TTI-622
Drug: Daratumumab Hyaluronidase-fihj
Ontorpacept (Code C125718)
Ontorpacept
ONTORPACEPT
SIRPa-Fc Fusion Protein TTI-621
SIRPaFc
TTI 621
TTI-621
SIRPa-IgG4-Fc Fusion Protein TTI-622 (Code C150756)
SIRPa-IgG4 Fc
SIRPa-IgG4 Fc TTI-622
SIRPa-IgG4-Fc Fusion Protein TTI-622
TTI 622
TTI-622
TTI622
Locations:
United States, New Jersey
United States, New York
Pfizer Completes Acquisition of Trillium Therapeutics